左西孟旦联合缬沙坦对慢性心力衰竭患者心肌损伤标志物的影响

目的 探讨左西孟旦联合缬沙坦对慢性心力衰竭患者心肌损伤标志物的影响.方法 回顾性分析2018年1月至2020年1月本院的98例慢性心力衰竭患者的临床资料,根据治疗方法 将患者分为联合治疗组(n=49,左西孟旦联合缬沙坦治疗)与单独治疗组(n=49,左西孟旦单独治疗).比较两组的心功能指标、临床疗效、血清心肌损伤标志物水...

Effect of levosimendan combined with valsartan on myocardial injury markers in patients with chronic heart failure

Objective To explore the effect of levosimendan combined with valsartan on myocardial injury markers in patients with chronic heart failure.Methods The clinical data of 98 patients with chronic heart failure in our hospital from January 2018 to January 2020 were retrospectively analyzed.According to the treatment methods,the patients were divided into combined treatment group(n=49,treated with levosimendan combined with valsartan)and single treatment group(n=49,treated with levosimendan alone).Cardiac function indexes,clinical efficacy,serum myocardial injury markers level and adverse reactions were compared between the two groups.Results After treatment,SV and LVEF in the combined treatment group were higher than those in the single treatment group(P<0.05).The total effective rate of treatment in the combined treatment group was higher than that in the single treatment group(P<0.05).After treatment,the serum NT-proBNP,cTnT,cTnI levels in the two groups decreased,and the serum IGF-1 level increased,and those in the combined treatment group were better than the single treatment group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Levosimendan combined with valsartan in the treatment of patients with chronic heart failure has significant effect,it can effectively reduce myocardial injury and improve cardiac function of patients.